US2009285908A1PendingUtilityA1

Method of treating endothelial injury

60
Individually held — no corporate assignee on recordPriority: Sep 11, 1996Filed: Jul 27, 2009Published: Nov 19, 2009
Est. expirySep 11, 2016(expired)· nominal 20-yr term from priority
Inventors:Athanasius A. AnagnostouGeorge Sigounas
A61P 9/14A61P 43/00A61P 35/04A61P 35/00A61P 9/10A61P 29/00A61K 38/1816A61P 17/02
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is described.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,
 wherein said endothelial injury is caused by mechanical damage, exposure to radiation, exposure to chemotherapeutic agents, inflammation, heart disease or cancer.   
     
     
         17 . The method according to  claim 16 , wherein said endothelial injury is caused by mechanical damage. 
     
     
         18 . The method according to  claim 16 , wherein said endothelial injury is caused by exposure to radiation. 
     
     
         19 . The method according to  claim 16 , wherein said endothelial injury is caused by inflammation. 
     
     
         20 . The method according to  claim 16 , wherein said endothelial injury is caused by heart disease. 
     
     
         21 . The method according to  claim 16 , wherein said endothelial injury is caused by cancer. 
     
     
         22 . The method according to  claim 16 , wherein said erythropoietin is administered intravenously or subcutaneously. 
     
     
         23 . A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,
 wherein said effective endothelial-protecting amount of erythropoietin reduces or prevents the suppression of endothelial growth associated with endothelial injury caused by mechanical damage, exposure to radiation, exposure to chemotherapeutic agents, inflammation, heart disease or cancer.   
     
     
         24 . A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,
 wherein said effective endothelial-protecting amount of erythropoietin increases the numbers of viable endothelial cells following endothelial injury caused by mechanical damage, exposure to radiation, exposure to chemotherapeutic agents, inflammation, heart disease or cancer.   
     
     
         25 . The method according to  claim 16 , wherein said erythropoietin is administered in an amount of from about 100 Units per kilogram to about 200 Units per kilogram. 
     
     
         26 . A method of reducing endothelial injury in a subject caused by administration of cisplatin to the subject, comprising administering an effective endothelial-protecting amount of erythropoietin in conjunction with the administration of cisplatin. 
     
     
         27 . The method according to  claim 26 , wherein said erythropoietin is administered intravenously or subcutaneously. 
     
     
         28 . The method according to  claim 26 , wherein said effective endothelial-protecting amount of erythropoietin is administered simultaneously with said cisplatin. 
     
     
         29 . The method according to  claim 26 , wherein said effective endothelial-protecting amount of erythropoietin is administered prior to said cisplatin. 
     
     
         30 . The method according to  claim 26 , wherein said effective endothelial-protecting amount of erythropoietin is administered after said cisplatin.

Join the waitlist — get patent alerts

Track US2009285908A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.